Abstract:Diabetes is a group of diseases marked by poor control of blood glucose levels. Diabetes mellitus (DM) occurs when pancreatic cells fail to make insulin, which is required to keep blood glucose levels stable, disorders, and so on. High glucose levels in the blood induce diabetic effects, which can cause catastrophic damage to bodily organs such as the eyes and lower extremities. Diabetes is classified into many forms, one of which is controlled by hyperglycemia or Diabetic Kidney Disease (DKD), and another that is not controlled by hyperglycemia (nondiabetic kidney disease or NDKD) and is caused by other factors such as hypertension, hereditary. DKD is associated with diabetic nephropathy (DN), a leading cause of chronic kidney disease (CKD) and end-stage renal failure. The disease is characterized by glomerular basement membrane thickening, glomerular sclerosis, and mesangial expansion, resulting in a progressive decrease in glomerular filtration rate, glomerular hypertension, and renal failure or nephrotic syndrome. It is also represented by some microvascular complications such as nerve ischemia produced by intracellular metabolic changes, microvascular illness, and the direct impact of excessive blood glucose on neuronal activity. Therefore, DKD-induced nephrotic failure is worse than NDKD. MicroRNAs (miRNAs) are important in the development and progression of several diseases, including diabetic kidney disease (DKD). These dysregulated miRNAs can impact various cellular processes, including inflammation, fibrosis, oxidative stress, and apoptosis, all of which are implicated during DKD. MiRNAs can alter the course of DKD by targeting several essential mechanisms. Understanding the miRNAs implicated in DKD and their involvement in disease development might lead to identifying possible therapeutic targets for DKD prevention and therapy. Therefore, this review focuses specifically on DKD-associated DN, as well as how in-silico approaches may aid in improving the management of the disease.

Noncoding RNAs and diabetic kidney disease

Noncoding RNAs as therapeutic targets in early stage diabetic kidney disease

Non-Coding RNAs as Biomarkers and Therapeutic Targets for Diabetic Kidney Disease

The role of long non‐coding RNAs in the development of diabetic kidney disease and the involved clinical application

MicroRNAs in diabetic nephropathy: functions, biomarkers, and therapeutic targets

Circular RNAs: An emerging precise weapon for diabetic nephropathy diagnosis and therapy

RNA-sequencing reveals genome-wide long non-coding RNAs profiling associated with early development of diabetic nephropathy

Understanding the Roles of Non-coding RNAs and Exosomal Non-Coding RNAs in Diabetic Nephropathy

LncRNA H19: a novel player in the regulation of diabetic kidney disease

MicroRNA as novel biomarkers and therapeutic targets in diabetic kidney disease: An update

Long Noncoding RNAs as Diagnostic and Therapeutic Targets in Type 2 Diabetes and Related Complications

Research Status of Differentially Expressed Noncoding RNAs in Type 2 Diabetes Patients

Small RNA sequencing reveals snoRNAs and piRNA-019825 as novel players in diabetic kidney disease

Whole transcriptome analysis of diabetic nephropathy in the db/db mouse model of type 2 diabetes

Long noncoding RNAs may impact podocytes and proximal tubule function through modulating miRNAs expression in Early Diabetic Kidney Disease of Type 2 Diabetes Mellitus patients

Dysregulated Urinary Extracellular Vesicle Small RNAs in Diabetic Nephropathy: Implications for Diagnosis and Therapy

The Functional Role of microRNAs and mRNAs in Diabetic Kidney Disease: A Review

Long non-coding RNAs: The hidden players in diabetes mellitus-related complications

Role of Extracellular Vesicles Derived Non-coding RNAs in Diabetic Kidney Disease

Current Insights into miRNA and lncRNA Dysregulation in Diabetes: Signal Transduction, Clinical Trials and Biomarker Discovery

Regulation of NcRNA-protein binding in diabetic foot